Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
A lack of correlation between activated partial thromboplastin time (aPTT), thrombin time (TT) and anti-factor Xa (AXa) activity was observed in patients after cardiac surgery with cardiopulmonary bypass (CBP). Indeed, AXa activity measured by the chromogenic assay, Coamatic Heparin, was higher than expected with regard to results obtained in coagulation assays. To account for this discrepancy, another AXa chromogenic assay was tested. First, AXa activity was measured with two chromogenic assays (Coamatic Heparin and Rotachrom Heparin) in plasma samples of 25 patients undergoing cardiac surgery at two time points after heparin reversal by protamine. AXa activity was significantly higher when measured with Coamatic Heparin than with Rotachrom Heparin in samples collected just after protamine infusion (p<0.01). Next, since Coamatic( Heparin contains dextran sulfate (DXS) to reduce the influence of heparin antagonists such as platelet factor 4 (PF4), whereas Rotachrom Heparin does not, we hypothesized that the dextran sulfate contained in the reagent might explain this discrepancy. We therefore performed in vitro studies consisting in neutralizing unfractionated heparin (UFH) with protamine and measuring AXa activity with the two chromogenic assays. An AXa activity was still measurable with Coamatic Heparin after neutralization, thus strongly suggesting that dextran sulfate dissociates protamine/heparin complexes. We conclude that Coamatic Heparin assays should be avoided when measuring AXa activity in plasma samples immediately after protamine infusion, as inaccurate results may lead to inadequate management of heparin reversal.
Mouton
Christine
C
Haemobiology Laboratory, Cardiologic Hospital, C.H.U de Bordeaux, Avenue Magellan, Pessac 33604, France. christine.muton@chu-bordeaux.fr
Calderon
Joachim
J
Janvier
Gérard
G
Vergnes
Marie-Christine
MC
D000925:Anticoagulants / Q000097:blood / Q000737:chemistry / Q000627:therapeutic use; D001780:Blood Coagulation Tests / Q000379:methods; D013504:Cardiovascular Surgical Procedures / Q000009:adverse effects; D002863:Chromogenic Compounds / Q000032:analysis / Q000737:chemistry; D016264:Dextran Sulfate / Q000097:blood* / Q000737:chemistry; D015951:Factor Xa / Q000032:analysis* / Q000737:chemistry; D006493:Heparin / Q000097:blood* / Q000737:chemistry / Q000627:therapeutic use; D006494:Heparin Antagonists / Q000097:blood / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007202:Indicators and Reagents / Q000737:chemistry; D011479:Protamines / Q000097:blood* / Q000737:chemistry / Q000627:therapeutic use; D011933:Reagent Kits, Diagnostic; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; D002863:Chromogenic Compounds; D006494:Heparin Antagonists; D007202:Indicators and Reagents; D011479:Protamines; D011933:Reagent Kits, Diagnostic; D006493:Heparin; D016264:Dextran Sulfate; D015951:Factor Xa